We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » COVID-19

COVID-19
COVID-19 RSS Feed RSS

CDC Expert Panel Endorses Pfizer, Moderna Boosters for All Adults

November 22, 2021
Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported the decision. Read More

AstraZeneca’s Dual-Antibody Injection Cuts Risk of COVID-19 Infection

November 19, 2021
AstraZeneca’s one-time dual-antibody injection cut the risk of symptomatic COVID-19 by up to 83 percent and the risk of severe disease by 88 percent in two studies of high-risk patients. Read More

Pfizer Inks $5.29 Billion Pact With U.S. to Supply COVID-19 Antiviral

November 19, 2021
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its experimental COVID-19 antiviral, Paxlovid (PF-07321332; ritonavir), to be delivered later this year and into 2022. Read More

U.S. to Buy More Doses of COVID-19 Antibody Drug From GSK, Vir

November 18, 2021
The companies said they will supply an unspecified number of doses by mid-December and that the government has an option to purchase additional doses through March 2022. Read More

Roche Ends Partnership With Atea to Develop COVID-19 Antiviral

November 18, 2021
Roche paid Atea $350 million upfront to co-develop the antiviral last year, but the companies have since lagged behind other drugmakers. Read More

Pfizer Applies for EUA for Its Oral COVID-19 Treatment, Inks Deal With Medicines Patent Pool

November 17, 2021
Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalization or death. Read More

Moderna Defends Against Myocarditis Fears in Conference Call

November 15, 2021
Faced with defending its COVID-19 vaccine in the face of troubling side effects, Moderna held a conference call late last week to discuss the risk of heart inflammation in young people. Read More

EMA Endorses COVID-19 Antibody Therapies From Regeneron-Roche, Celltrion

November 12, 2021
The European Medicines Agency (EMA) has given the thumbs up to two COVID-19 antibody therapies from Regeneron-Roche and Celltrion Healthcare, paving the way for imminent approval by the European Commission. Read More

EU Adds Rare Spinal Condition to J&J COVID-19 Side Effects

November 12, 2021
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects. Read More

AstraZeneca to Create Distinct Vaccine and Antibodies Business

November 11, 2021
AstraZeneca is setting up a new business unit dedicated to overseeing its vaccines and antibody therapies as it looks to rebound from pandemic-era disappointments related to its COVID-19 jab co-developed with Oxford University. Read More

FDA Gives Inovio Green Light for Phase 3 Trial of DNA COVID-19 Vaccine

November 11, 2021
Inovio has received the FDA go-ahead for a phase 3 trial of INO-4800, a DNA plasmid vaccine against COVID-19. Read More

Moderna and NIH Dig in Over COVID-19 Vaccine Patent Dispute

November 11, 2021
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists. Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 164 165 Next

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 15Jun

    Recall Readiness: Dust Off Your SOPs, There’s a New Guidance in Town

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • MedMira Gets CE Mark for Its Multiplo Syphilis Antibody Test

  • FDA Lifts Clinical Hold on Ocugen COVID-19 Vaccine Clinical Trial

  • FDA Refuses Second Clearance to NeuroOne’s Evo sEEG Electrode

  • FDA Greenlights Dermavant’s Vtama Cream for Psoriasis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing